European Reference Networks: challenges and opportunities
- PMID: 33733400
- PMCID: PMC7968406
- DOI: 10.1007/s12687-021-00521-8
European Reference Networks: challenges and opportunities
Abstract
European Reference Networks (ERNs) were founded on the principle that many rare disease (RD) issues are pan-European and any single Member State cannot solve them alone. In 2021, ERNs are already in the deployment stage; however, their day-to-day functioning and realization of their potential are still severely hampered by many challenges, including issues in governance and regulation, lack of legal status, insufficient and unsustainable funding, lack of ERN integration into national systems, endangered collaboration with UK RD experts due to Brexit, insufficient exploitation of ERN potential in RD research, underappreciation of highly qualified human resources, problems with the involvement of patient representatives, and still unclear place of ERNs in the overall European RD and digital ecosystem. Bold and innovative solutions that must be taken to solve these challenges inevitably involve pan-European collaboration across several sectors and among multistakeholder RD communities and in many cases crucially rely on the constructive dialogue and coherent, united decisions of national and European authorities that are based on common EU values. Importantly, unresolved challenges may have a strong impact on the further sustainability of ERNs and their ability to realize full potential in addressing huge unmet needs of RD patients and their families.
Conflict of interest statement
Dr. Graessner received consulting fees from Roche. He has received a speaker honorarium from Takeda. The co-authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Similar articles
-
The pooling of manpower and resources through the establishment of European reference networks and rare disease patient registries is a necessary area of collaboration for rare renal disorders.Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv9-14. doi: 10.1093/ndt/gfu094. Nephrol Dial Transplant. 2014. PMID: 25165190 Review.
-
Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases.Eur J Hum Genet. 2021 Sep;29(9):1325-1331. doi: 10.1038/s41431-021-00859-0. Epub 2021 Jun 1. Eur J Hum Genet. 2021. PMID: 34075208 Free PMC article.
-
The European Reference Network for Rare Neurological Diseases.Front Neurol. 2021 Jan 14;11:616569. doi: 10.3389/fneur.2020.616569. eCollection 2020. Front Neurol. 2021. PMID: 33519696 Free PMC article. Review.
-
ERN BOND: The key European network leveraging diagnosis, research, and treatment for rare bone conditions.Eur J Med Genet. 2024 Apr;68:104916. doi: 10.1016/j.ejmg.2024.104916. Epub 2024 Feb 1. Eur J Med Genet. 2024. PMID: 38296035
-
Domain-Specific Common Data Elements for Rare Disease Registration: Conceptual Approach of a European Joint Initiative Toward Semantic Interoperability in Rare Disease Research.JMIR Med Inform. 2022 May 20;10(5):e32158. doi: 10.2196/32158. JMIR Med Inform. 2022. PMID: 35594066 Free PMC article.
Cited by
-
An ontology-based rare disease common data model harmonising international registries, FHIR, and Phenopackets.Sci Data. 2025 Feb 8;12(1):234. doi: 10.1038/s41597-025-04558-z. Sci Data. 2025. PMID: 39922817 Free PMC article.
-
Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.Front Pharmacol. 2022 Jan 21;12:750742. doi: 10.3389/fphar.2021.750742. eCollection 2021. Front Pharmacol. 2022. PMID: 35126102 Free PMC article. Review.
-
Pediatric to adult care transfer in rare liver diseases: Recommendations based on insights from a European omnistakeholder event.JHEP Rep. 2025 Mar 26;7(6):101403. doi: 10.1016/j.jhepr.2025.101403. eCollection 2025 Jun. JHEP Rep. 2025. PMID: 40496441 Free PMC article.
-
Criteria to evaluate unmet health-related needs of persons living with rare diseases and their caregivers: rapid literature review and stakeholder consultations.Orphanet J Rare Dis. 2025 Jul 1;20(1):321. doi: 10.1186/s13023-025-03838-6. Orphanet J Rare Dis. 2025. PMID: 40598354 Free PMC article. Review.
-
How to balance valuable innovation with affordable access to medicines in Belgium?Front Pharmacol. 2022 Sep 16;13:960701. doi: 10.3389/fphar.2022.960701. eCollection 2022. Front Pharmacol. 2022. PMID: 36188534 Free PMC article.
References
-
- Commission Delegated Decision of 10 March 2014 setting out criteria and conditions that European Reference Networks and healthcare providers wishing to join a European Reference Network must fulfil (2014). Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014D0286
-
- Commission Implementing Decision of 10 March 2014 setting out criteria for establishing and evaluating European Reference Networks and their members and for facilitating the exchange of information and expertise on establishing and evaluating such Networks (2014). Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ%3AJOL_2014_147_R_...
-
- European Commission website. European Reference Networks (n.d.) Available at: https://ec.europa.eu/health/ern_en. Accessed 5 Aug 2020
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous